San Diego – June 1, 2016 – Cooley is advising Jazz Pharmaceuticals on its $1.5 billion acquisition of Celator. The transaction will add to Jazz's portfolio the orphan drug VYXEOS, which aims to treat AML. The deal is expected to close in Q3 2016.
Jazz Pharmaceuticals, a Cooley client since 2006, is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs.
Celator Pharmaceuticals is an oncology-focused biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer.
The Cooley M&A team advising Jazz Pharmaceuticals includes Barbara Borden, Marya Postner, Chad Mills, Ben Beerle, Matt Silverman, Susan Walker and Edmond Lay.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.
"Jazz Pharmaceuticals Agrees to Buy Celator for About $1.5 Billion," The Wall Street Journal
"Jazz Pharmaceuticals to Buy Celator for $1.5 Billion," The New York Times
"Jazz Pharmaceuticals Agrees to Buy Celator for $1.5 Billion," Bloomberg
"Jazz Pharmaceuticals to Buy Celator in $1.5 Billion Deal," Reuters
"Jazz Pharmaceuticals Agrees to Purchase Celator," The Recorder
"Dealmakers: Jazz Pharma Buys Cancer Treatment Provider in $1.5B Deal with Help from Cooley, Kirkland," Daily Journal (Subscription required)